



Press release

STADA: Domination and profit and loss transfer agreement between STADA Arzneimittel AG and Nidda Healthcare GmbH takes effect / beginning of acceptance period for severance offer

Bad Vilbel, March 20, 2018 – The domination and profit and loss transfer agreement (DPLA) between Nidda Healthcare GmbH (Nidda Healthcare) as the controlling entity and STADA Arzneimittel AG (STADA) as the dependent company was entered into the commercial register of the Company at the District Court of Frankfurt am Main on March 20, 2018. The inter-company agreement that was approved by STADA's Extraordinary General Meeting on February 2, 2018 thus takes effect.

STADA shareholders now have the opportunity to tender their shares to Nidda Healthcare in return for a compensation in the amount of €74.40 per share through their custodian bank. The acceptance period for this offer expires two months after the day on which the entry of the DPLA in the commercial register pursuant to Section 10 of the German Commercial Code (*HGB*) was announced. Should a duly submitted petition for a court ruling on the severance or the compensation be made to the court determined in Section 2 of the German Act on Appraisal Proceedings (*Spruchverfahrensgesetz*), the period shall end two months after the day on which the last petition that is decided upon is announced in the Federal Gazette (*Bundesanzeiger*).

Those remaining STADA shareholders who do not accept the severance offer remain shareholders of the Company and receive for the duration of the contract – instead of an annual dividend – a recurring compensation payment payable for each full fiscal year of STADA for each STADA share in the amount of €3.82 gross or €3.53 net at current tax rates.

Executive Board: Dr. Claudio Albrecht (Chairman) / Mark Keatley / Dr. Barthold Piening
Chairman of the Supervisory Board: Dr. Günter von Au



About STADA Arzneimittel AG

STADA Arzneimittel AG is a publicly-listed company with headquarters in Bad Vilbel, Germany. STADA consistently focuses on a multi-pillar strategy of generics and branded products (OTC) with an increasingly international market orientation. Worldwide, STADA is represented in about 30 countries with roughly 50 subsidiaries. Branded products such as Grippostad and Ladival are among the highest selling in their product categories in Germany. In financial year 2017, STADA achieved adjusted Group sales of Euro 2,255.3 million, adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of Euro 433.9 million and adjusted net income of Euro 195.6 million. As of December 31, 2017, STADA employed 10,176 people worldwide.

Executive Board: Dr. Claudio Albrecht (Chairman) / Mark Keatley / Dr. Barthold Piening
Chairman of the Supervisory Board: Dr. Günter von Au